- Home
- IDYA
as 11-15-2024 4:00pm EST
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 2.6B | IPO Year: | 2019 |
| Target Price: | $53.08 | AVG Volume (30 days): | 750.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.34 | EPS Growth: | N/A |
| 52 Week Low/High: | $26.41 - $47.74 | Next Earning Date: | 11-04-2024 |
| Revenue: | $3,922,000 | Revenue Growth: | -83.30% |
| Revenue Growth (this year): | -69.08% | Revenue Growth (next year): | 158.10% |
Latest IDEAYA Biosciences Inc. News
IDYA Breaking Stock News: Dive into IDYA Ticker-Specific Updates for Smart Investing
PR Newswire
5 days ago
IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day
MT Newswires
6 days ago
IDEAYA Biosciences Exercises Option to Develop Biocytogen's Potential Cancer Treatment
Business Wire
6 days ago
Biocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise
PR Newswire
6 days ago
IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen
Zacks
10 days ago
Wall Street Analysts Predict an 81.88% Upside in IDEAYA Biosciences (IDYA): Here's What You Should Know
MT Newswires
12 days ago
Leerink Partners Downgrades IDEAYA Biosciences to Market Perform, $27 Price Target
Simply Wall St.
12 days ago
IDEAYA Biosciences Third Quarter 2024 Earnings: US$0.60 loss per share (vs US$0.46 loss in 3Q 2023)
PR Newswire
13 days ago
/C O R R E C T I O N -- IDEAYA Biosciences, Inc./
Compare IDYA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IDYA IDEAYA Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.